Pharmaceutics, 2022 Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet +15 more
doaj +1 more source
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]
, 2015 BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying +2 more
core +1 more source
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]
, 2016 BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier +10 more
core +2 more sources
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]
, 2008 Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Abrey LE +13 more
core +1 more source
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer [PDF]
, 2016 BACKGROUND A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ...
Birrer, Michael J. +14 more
core +3 more sources
Conversion of a gastric band into an intraperitoneal port in a patient with optimally debulked stage 3C serous ovarian carcinoma [PDF]
, 2015 Intraperitoneal (IP) chemotherapy in women with optimally debulked stage 3 ovarian cancer improves overall survival and progression-free survival, and its use has been encouraged in the adjuvant treatment of appropriately selected patients (Armstrong et ...
Cohen, P, Tan, J, Tan, J, Tucker, P
core +2 more sources
A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]
, 2016 Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis +10 more
core +1 more source
Cancer Treatment and Research Communications, 2021 Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Manasi Sheth, Jinnie Ko
doaj +1 more source
The next steps in improving the outcomes of advanced ovarian cancer [PDF]
, 2015 Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication.
Blagden, S +3 more
core +1 more source
Who Is In Charge, and Who Should Be? The Disciplinary Role of the Commander in Military Justice Systems [PDF]
, 2006 BackgroundStandard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma ...
Abrey, Lauren +13 more
core +3 more sources